{"id":6589,"date":"2023-07-07T20:12:25","date_gmt":"2023-07-07T20:12:25","guid":{"rendered":"https:\/\/www.sicklecelldisease.org\/?p=6589"},"modified":"2023-07-07T20:12:25","modified_gmt":"2023-07-07T20:12:25","slug":"marac-statement-crizanlizumab-adakveo","status":"publish","type":"post","link":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/","title":{"rendered":"MARAC Statement: Crizanlizumab (Adakveo)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\" alt=\"\" width=\"2500\" height=\"521\" class=\"alignnone size-full wp-image-4598\" srcset=\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg 2500w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-600x125.jpg 600w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-300x63.jpg 300w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-1024x213.jpg 1024w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-768x160.jpg 768w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-1536x320.jpg 1536w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-2048x427.jpg 2048w, https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3-1568x327.jpg 1568w\" sizes=\"auto, (max-width: 2500px) 100vw, 2500px\" \/><\/p>\n<p>July 7, 2023 &#8211; SCDAA\u2019s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, 2023, that the conditional marketing authorization for crizanlizumab (Adakveo) be revoked. The EMA stated that this revocation was triggered by the findings of the Novartis STAND multinational clinical trial showing no significant benefit of crizanlizumab over placebo in reducing pain or hospitalizations. Novartis reports that there were no safety problems in STAND. Abstract PB2512 submitted to the 2023 European Hematology Association reports no new safety issues in Novartis\u2019 post-marketing surveillance of over 5,000 patient-treatment-years.<\/p>\n<p>Crizanlizumab was given United States Food and Drug Administration (FDA) approval in November 2019 and remains on the market in the U.S. Americans with sickle cell disease are still receiving this treatment. MARAC urges the FDA to keep crizanlizumab available for use in the U.S. while it awaits more detailed examination of the data so that individuals with sickle cell disease can benefit from this treatment.<\/p>\n<p><a href=\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2023\/07\/H-4147-MARAC-Statement-Adaveko.pdf\">Read the full statement here.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>July 7, 2023 &#8211; SCDAA\u2019s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, 2023, that the conditional marketing authorization for crizanlizumab (Adakveo) be revoked. The EMA stated that this revocation was triggered by the findings of the Novartis [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-6589","post","type-post","status-publish","format-standard","hentry","category-marac-statement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"og:description\" content=\"July 7, 2023 &#8211; SCDAA\u2019s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, 2023, that the conditional marketing authorization for crizanlizumab (Adakveo) be revoked. The EMA stated that this revocation was triggered by the findings of the Novartis [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/\" \/>\n<meta property=\"og:site_name\" content=\"Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-07T20:12:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\" \/>\n<meta name=\"author\" content=\"Emma Day\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emma Day\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/\",\"url\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/\",\"name\":\"MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\",\"datePublished\":\"2023-07-07T20:12:25+00:00\",\"dateModified\":\"2023-07-07T20:12:25+00:00\",\"author\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#primaryimage\",\"url\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\",\"contentUrl\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\",\"width\":2500,\"height\":521},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sicklecelldisease.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MARAC Statement: Crizanlizumab (Adakveo)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\",\"url\":\"https:\/\/www.sicklecelldisease.org\/\",\"name\":\"Sickle Cell Disease Association of America Inc.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3\",\"name\":\"Emma Day\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g\",\"caption\":\"Emma Day\"},\"url\":\"https:\/\/www.sicklecelldisease.org\/author\/emma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/","og_locale":"en_US","og_type":"article","og_title":"MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.","og_description":"July 7, 2023 &#8211; SCDAA\u2019s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, 2023, that the conditional marketing authorization for crizanlizumab (Adakveo) be revoked. The EMA stated that this revocation was triggered by the findings of the Novartis [&hellip;]","og_url":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/","og_site_name":"Sickle Cell Disease Association of America Inc.","article_published_time":"2023-07-07T20:12:25+00:00","og_image":[{"url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","type":"","width":"","height":""}],"author":"Emma Day","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Emma Day","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/","url":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/","name":"MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.","isPartOf":{"@id":"https:\/\/www.sicklecelldisease.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#primaryimage"},"image":{"@id":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","datePublished":"2023-07-07T20:12:25+00:00","dateModified":"2023-07-07T20:12:25+00:00","author":{"@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3"},"breadcrumb":{"@id":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#primaryimage","url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","contentUrl":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","width":2500,"height":521},{"@type":"BreadcrumbList","@id":"https:\/\/www.sicklecelldisease.org\/2023\/07\/07\/marac-statement-crizanlizumab-adakveo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sicklecelldisease.org\/"},{"@type":"ListItem","position":2,"name":"MARAC Statement: Crizanlizumab (Adakveo)"}]},{"@type":"WebSite","@id":"https:\/\/www.sicklecelldisease.org\/#website","url":"https:\/\/www.sicklecelldisease.org\/","name":"Sickle Cell Disease Association of America Inc.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3","name":"Emma Day","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g","caption":"Emma Day"},"url":"https:\/\/www.sicklecelldisease.org\/author\/emma\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/6589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/comments?post=6589"}],"version-history":[{"count":2,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/6589\/revisions"}],"predecessor-version":[{"id":6591,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/6589\/revisions\/6591"}],"wp:attachment":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/media?parent=6589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/categories?post=6589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/tags?post=6589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}